Gilead Sciences Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Gilead Sciences is de winst gegroeid met een gemiddeld jaarlijks percentage van 2.4%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 4.8% per jaar. Het rendement op eigen vermogen van Gilead Sciences is 5.7%, en het heeft een nettomarge van 3.8%.

Belangrijke informatie

2.4%

Groei van de winst

2.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	4.8%
Rendement op eigen vermogen	5.7%
Nettomarge	3.8%
Volgende winstupdate	06 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Apr 22

Gilead Sciences: Some Signs Of An Impending Bottom

Apr 22

Gilead Sciences: Realizing Financial Projections Is Key

Mar 20

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13

Opbrengsten en kosten

Hoe Gilead Sciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:GILD Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	27,805	1,054	5,099	5,728
31 Mar 24	27,450	485	5,580	5,778
31 Dec 23	27,116	5,665	5,537	5,758
30 Sep 23	27,391	5,876	6,502	5,880
30 Jun 23	27,382	5,484	6,401	5,578
31 Mar 23	27,043	5,583	5,909	5,280
31 Dec 22	27,281	4,592	5,673	4,998
30 Sep 22	27,136	3,334	5,303	4,768
30 Jun 22	27,515	4,137	5,280	4,727
31 Mar 22	27,472	4,515	5,274	4,714
31 Dec 21	27,305	6,225	5,246	4,601
30 Sep 21	27,482	7,394	5,083	4,655
30 Jun 21	26,638	5,162	4,999	4,713
31 Mar 21	25,564	301	4,887	4,924
31 Dec 20	24,689	123	5,112	4,927
30 Sep 20	23,147	1,268	4,625	4,560
30 Jun 20	22,174	-257	4,571	4,432
31 Mar 20	22,716	4,962	4,427	4,002
31 Dec 19	22,449	5,386	4,381	4,055
30 Sep 19	22,365	2,693	4,308	4,086
30 Jun 19	22,357	5,955	4,204	3,995
31 Mar 19	22,320	5,892	4,089	4,318
31 Dec 18	22,127	5,455	4,056	3,920
30 Sep 18	22,281	1,587	4,177	4,218
30 Jun 18	23,197	2,208	4,108	4,068
31 Mar 18	24,690	3,464	4,025	3,740
31 Dec 17	26,107	4,628	3,878	3,734
30 Sep 17	27,478	11,601	3,618	3,591
30 Jun 17	28,466	12,213	3,570	3,826
31 Mar 17	29,101	12,637	3,563	4,446
31 Dec 16	30,390	13,501	3,398	4,666
30 Sep 16	31,576	15,076	3,472	4,416
30 Jun 16	32,371	16,346	3,544	4,135
31 Mar 16	32,839	17,341	3,466	3,469
31 Dec 15	32,639	18,108	3,426	3,014
30 Sep 15	31,447	16,912	3,236	2,952
30 Jun 15	29,194	15,043	3,278	2,839
31 Mar 15	27,485	14,207	3,080	2,608
31 Dec 14	24,890	12,101	2,983	2,854
30 Sep 14	20,696	9,406	2,561	2,409
30 Jun 14	17,437	7,463	2,023	2,295
31 Mar 14	13,669	4,580	1,814	2,220
31 Dec 13	11,202	3,075	1,699	2,120

Kwaliteitswinsten: GILD heeft een grote eenmalige verlies van $8.5B wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: De huidige netto winstmarges (3.8%) GILD } zijn lager dan vorig jaar (20%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van GILD is de afgelopen 5 jaar met 2.4% per jaar gegroeid.

Versnelling van de groei: De winstgroei GILD is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: GILD had het afgelopen jaar een negatieve winstgroei ( -80.8% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Biotechs ( -2.3% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 5.7% ) van GILD wordt als laag beschouwd.

Gilead Sciences Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Recent updates

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Chief Medical Officer notifies of intention to sell stock

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Chief Commercial Officer notifies of intention to sell stock

Upcoming dividend of US$0.77 per share

Gilead Sciences: Buy This Bargain Before It's Gone

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Consensus EPS estimates fall by 21%

Second quarter dividend of US$0.77 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

A Look At Gilead Sciences After Its Recent Weakness

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Records Positive Phase III Results In HIV

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden